Assay Prediction |
Pathology |
Clinical Features |
Tissue of Origin |
Veridex |
Histology |
IHC |
Age/Sex |
Sites of Metastasis |
Intrathoracic Location (Y/N) |
Response to Treatment |
Survival (mo) |
NSCLC |
NSCLC |
PD adenocarcinoma |
TTF1+, CEA+, Pan-CK+, S100- |
45/F |
bone, soft tissue |
N |
PD |
8 |
NSCLC |
NSCLC |
PD carcinoma |
CK AE1/AE3+, HMB45-, CK20-, CK7+, AFP-, BhCG- |
54/F |
lymph nodes |
Y |
CR |
65 |
NSCLC |
NSCLC |
PD carcinoma |
CK7+, CEA+, B14/18+, S100-, PSA-, PSAP-, HMB45- |
60/M |
kidney, spleen |
N |
PD |
9 |
NSCLC |
NSCLC |
PD carcinoma |
CK+, EMA+, CD30-, LCA- |
74/M |
liver, lung, lymph nodes |
Y |
PR |
24 |
NSCLC |
NSCLC |
PD carcinoma |
AE1/AE3+, chromogranin-, synaptophysis-, S100-, HMB45-, LCA- |
64/M |
liver, lung, lymph nodes, kidney |
Y |
PR |
8 |
NSCLC |
NSCLC |
PD carcinoma |
None |
68/M |
pancreas, lymph nodes, lung |
Y |
SD |
14 |
NSCLC |
Colon |
Squamous |
None |
59/M |
lymph nodes, soft tissue |
Y |
PD |
6 |
NSCLC |
Other |
Squamous |
None |
43/M |
liver, lung, bone, lymph nodes |
Y |
PR |
11 |
NSCLC |
Other |
PD adenocarcinoma |
None |
72/F |
lung |
Y |
PD |
30 |
NSCLC |
Pancreas |
PD adenocarcinoma |
None |
65/M |
abdomen, lung, bone |
Y |
UE |
<1 |
NSCLC |
Pancreas |
PD adenocarcinoma |
None |
54/M |
lymph nodes |
Y |
PR |
33+ |
Ovarian |
NSCLC |
PD adenocarcinoma |
CK+, CEA+, CK20+, ER-, PR-, HMB45-, S100-, CK7-, Her2/neu- |
51/F |
lung, liver, lymph nodes |
Y |
PD |
5 |
Colorectal |
NSCLC |
PD adenocarcinoma |
CK20+, CK+, PLAP-, PSA/PSAP-, melanin A- |
71/M |
abdomen, soft tissue |
N |
SD |
21 |
Bladder |
NSCLC |
Squamous |
None |
60/M |
Soft tissue |
N |
UE |
32 |
Non-diagnostic |
NSCLC |
Squamous |
TTF1- |
55/M |
lung, soft tissue |
Y |
SD |
9 |
|
